A seven-amino-acid peptide that blocks the brain's "leak channel" for depression at picomolar potency, triggers new neuron growth in four days—and has never been tested in a single human being

In 2006, a research team at the CNRS in Nice, France, made a discovery that reshaped thinking about depression neurobiology: mice lacking the gene for a potassium channel called TREK-1 (KCNK2) were resistant to depression across five separate behavioral models—forced swim test, tail suspension test, conditioned suppression of motility, learned helplessness, and novelty-suppressed feeding. TREK-1 knockout mice behaved as though they were permanently on antidepressants.

This finding made TREK-1 a drug target. If blocking this single ion channel could replicate the effect of antidepressants—potentially without the weeks-long onset delay and the sexual dysfunction, weight gain, and emotional blunting that limit SSRIs—it would represent a genuine advance in depression pharmacology. The question was how to block TREK-1 selectively without affecting the hundreds of other potassium channels in the brain.

The answer came from an unexpected source: sortilin, a protein involved in trafficking growth factors. During the proteolytic maturation of sortilin, a 17-amino-acid peptide called spadin is released—and spadin turned out to be a natural TREK-1 antagonist. PE-22-28 is a shortened version of spadin (residues 22–28 of the sortilin propeptide region)—seven amino acids that retain full TREK-1 blocking activity at 300-fold greater potency than the parent compound, with a duration of action extended from 7 hours to 23 hours.

Quick Facts: PE-22-28 at a Glance

What Is PE-22-28?

Pronunciation: P-E-twenty-two-twenty-eight

Your neurons maintain a resting electrical charge by pumping potassium ions out through channels in their membranes. TREK-1 (also called KCNK2) is one of these potassium channels—a two-pore domain channel that helps set the baseline electrical excitability of neurons. When TREK-1 is open, potassium flows out, the neuron stays quiet. When TREK-1 is blocked, less potassium escapes, the neuron becomes more excitable—more likely to fire.

In the dorsal raphe nucleus—the brain's main serotonin factory—increased neuronal excitability means more serotonin release. This is functionally equivalent to what SSRIs do (increase serotonin availability), but through a completely different mechanism: where SSRIs prevent serotonin reuptake after it has been released, TREK-1 blockers cause more serotonin to be released in the first place.

PE-22-28 is a synthetic seven-amino-acid peptide derived from spadin—a natural peptide released during the processing of a protein called sortilin. Spadin was the first identified endogenous TREK-1 antagonist. PE-22-28 is the optimized version: shorter (7 amino acids vs. 17), more potent (IC50 = 0.12 nM vs. 40–60 nM for spadin), and longer-acting (23 hours vs. 7 hours).

Origins and Discovery

PE-22-28's story begins with a 2006 discovery in Nice, France. Catherine Heurteaux and colleagues at the CNRS Institut de Pharmacologie Moléculaire et Cellulaire (IPMC) characterized TREK-1 knockout mice and found they were resistant to depression across all five standard behavioral tests. This was the first demonstration of a single ion channel whose deletion produced a comprehensive antidepressant phenotype.

The search for a TREK-1 blocker led to an unexpected source. In 2010, Jean Mazella and colleagues at the same institute discovered that spadin—a peptide naturally released during the maturation of sortilin—specifically blocks TREK-1 at nanomolar concentrations (PMID 20405001). Spadin was endogenous, selective, and produced rapid antidepressant effects in rodents (within 4 days of sub-chronic treatment, vs. 3–4 weeks for SSRIs).

The limitation was spadin's short duration of action (~7 hours) and moderate potency. Alaeddine Djillani, working in the same CNRS/IPMC group, systematically truncated spadin to identify the minimal active fragment. PE-22-28—residues 22-28 of the sortilin propeptide—retained full TREK-1 blocking activity at 300-fold greater potency and with three-fold longer duration of action (PMID 28955242).

The entire research program—from TREK-1 knockout through spadin discovery through PE-22-28 optimization—has been conducted at a single institution: the CNRS/IPMC in Valbonne/Nice.

Mechanism of Action

TREK-1 Selective Antagonism

PE-22-28 blocks the TREK-1 (KCNK2) two-pore domain potassium channel with an IC50 of 0.12 nM—approximately 300-500 times more potent than spadin (40–60 nM). Selectivity testing confirms PE-22-28 does not significantly affect other K2P family channels (TREK-2, TRAAK, TASK-1, TASK-3) or classical potassium channels at therapeutic concentrations (PMID 28955242). This selectivity is critical—non-selective potassium channel blockers can cause cardiac arrhythmias and seizures.

Rapid Neurogenesis

PE-22-28 induces hippocampal neurogenesis after only 4 days of sub-chronic treatment (PMID 28955242). Conventional antidepressants (SSRIs) require 3-4 weeks to induce comparable neurogenic effects. This rapid onset of neurogenesis is proposed as the mechanism underlying PE-22-28's rapid antidepressant action in rodent behavioral models.

BDNF Upregulation

Treatment rapidly increases BDNF expression in the hippocampus. As with P21, this may be a downstream consequence of neurogenesis rather than a direct PE-22-28 mechanism—but the functional outcome (enhanced neuroplasticity) is the same.

Biphasic Dose-Response

PE-22-28 exhibits a biphasic dose-response relationship that is pharmacologically important (PMID 31325429): - Low doses (0.03 mcg/kg): Activate TREK-1 → neuroprotection (TREK-1 opening protects neurons during ischemia) - High doses (3 mcg/kg): Inhibit TREK-1 → antidepressant and neurogenic effects

This biphasic pharmacology means the dose determines whether PE-22-28 is neuroprotective or antidepressant—the difference between activating and blocking the same channel. This complicates dosing for community users who may not know which side of the dose curve they are on.

Neuroprotection in Stroke Models

At low doses, PE-22-28 showed neuroprotective effects in mouse MCAO (stroke) models—preventing body weight loss, delaying dopaminergic degeneration, improving motor and cognitive deficits, and preventing post-stroke depression (PMID 31325429).

Key Research Areas and Studies

Depression

PE-22-28's primary proposed application is as a rapid-acting antidepressant. In the forced swim test and novelty-suppressed feeding test, PE-22-28 produced antidepressant-like effects after only 4 days of sub-chronic treatment—dramatically faster than the 3-4 weeks required for SSRIs (PMID 28955242). If this translates to humans, it could address one of the most significant limitations of current antidepressant pharmacology: the lag time between starting medication and feeling better.

Stroke Recovery

At neuroprotective (low) doses, PE-22-28 improved outcomes in mouse stroke models—including preventing post-stroke depression, a common complication that worsens recovery (PMID 31325429).

Neurogenesis

The rapid neurogenesis (4-day onset) is PE-22-28's most distinctive pharmacological property. If confirmed in humans, it would suggest that TREK-1 antagonism may be a more direct route to hippocampal neurogenesis than SSRI treatment.

Single-Lab Science—The Strength and the Risk

Every published data point for PE-22-28 originates from one research group: the Djillani/Mazella/Heurteaux/Moha ou Maati group at CNRS UMR 7275, Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d'Azur, Valbonne/Nice, France.

This is a respected academic institution with a coherent multi-year research program. The progression from TREK-1 knockout characterization through spadin discovery through PE-22-28 optimization is methodologically sound and published in peer-reviewed journals (Frontiers in Pharmacology, Neuropharmacology, PLoS Biology). The electrophysiology is rigorous, the selectivity screening is thorough, and the behavioral pharmacology follows standard protocols.

But single-lab science has inherent limitations. Every positive finding could be confirmed or contradicted by an independent group—and until that replication happens, the results are provisional. The history of pharmacology includes many compounds that showed consistent effects in one laboratory's hands and failed to replicate when other groups tried. This is not a criticism of the Nice group—it is a structural limitation of unreplicated science.

The peptide vendor community does not typically distinguish between "published in a peer-reviewed journal" and "independently replicated." PE-22-28 is marketed as though the preclinical data constitutes evidence of human efficacy. It does not. The data constitutes evidence that further research is warranted—which is a very different statement.

Claims vs. Evidence

The Human Evidence Landscape

There is no human evidence for PE-22-28. Zero clinical trials. Zero human pharmacokinetic studies. Zero human safety studies.

The compound has never been administered to a human being in any controlled clinical setting. The entire evidence base consists of rodent behavioral pharmacology, in vitro electrophysiology, and mouse stroke models—all from one laboratory in Nice, France.

Safety, Risks, and Limitations

No Human Safety Data

Zero human studies of any kind. No toxicology, no reproductive toxicity, no carcinogenicity, no drug interaction studies.

TREK-1 Is Not Just a Depression Channel

TREK-1 is expressed throughout the CNS and in several peripheral tissues. Its roles include: - Neuroprotection during ischemia: TREK-1 opening is protective during brain ischemia. Chronic TREK-1 blockade could theoretically increase vulnerability to stroke. - Pain processing: TREK-1 modulates pain perception. Blockade could alter pain thresholds. - Anesthetic sensitivity: TREK-1 channels contribute to volatile anesthetic sensitivity. - Thermoregulation: TREK-1 plays a role in temperature sensing.

Chronic systemic TREK-1 blockade may have consequences beyond antidepressant effects that have not been characterized.

Biphasic Dose-Response Concern

The difference between neuroprotective (low dose, TREK-1 activation) and antidepressant (high dose, TREK-1 blockade) effects depends on dose. For community users dosing with research chemicals of uncertain concentration, this biphasic pharmacology creates unpredictable effects.

Seizure Risk

TREK-1 has anticonvulsant properties (channel opening stabilizes neuronal membrane potential). However, spadin-treated mice paradoxically showed increased seizure resistance—possibly through BDNF-mediated mechanisms. The net effect of chronic TREK-1 blockade on seizure threshold in humans is unknown.

Legal and Regulatory Status

Worldwide: Not approved in any country for any indication.

United States: No IND. No regulatory engagement. Legal status is research chemical.

WADA: Not explicitly listed on the Prohibited List.

Research Protocols and Formulation Considerations

Research Formulation

Available as lyophilized peptide from research chemical vendors. Reconstituted for injection.

Route Considerations

All published animal data uses intraperitoneal injection. Community use is subcutaneous. No intranasal data has been published.

Dosing in Published Research

No human dose of PE-22-28 has ever been established. All published dosing data comes from a single laboratory at the CNRS in Nice, France, using mouse models with intraperitoneal injection. A critical feature of PE-22-28 pharmacology is its biphasic dose-response: low doses (~0.03 mcg/kg) activate TREK-1 and produce neuroprotective effects, while higher doses (~3 mcg/kg) block TREK-1 and produce antidepressant effects—a 100-fold difference that creates significant precision demands. The table below summarizes the only published animal dosing data.

Published Animal Dosing

Key Points

• Biphasic: 0.03 mcg/kg = neuroprotective; 3 mcg/kg = antidepressant (100-fold difference)
• No human dose has been established
• No human PK/PD data exists
• The 100-fold dose gap between neuroprotective and antidepressant effects creates precision demands

Dosing in Self-Experimentation Communities

PE-22-28 is sold by multiple peptide vendors and used in online communities (Reddit r/peptides, r/nootropics) for mood enhancement, cognitive improvement, and antidepressant purposes. Community dosing protocols are entirely anecdotal—no published human PK/PD data informs dosing.

Community-reported effects include improved mood, enhanced mental clarity, and subjective antidepressant effects—consistent with the proposed mechanism but not validated by controlled observation.

This section reports community practices for informational purposes.

Combination Stacks

Research into PE-22-28 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining PE-22-28 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

PE-22-28 has one of the clearest pharmacological profiles in Cluster E: a selective TREK-1 antagonist with 300-fold greater potency than its parent compound, rapid neurogenesis induction (4 days), and consistent antidepressant effects in rodent behavioral models. The TREK-1 mechanism is a genuinely novel approach to depression pharmacology. The selectivity data is rigorous. The behavioral pharmacology is consistent.

Everything that is known comes from one lab. No independent group has published a replication. No human has received PE-22-28 in a controlled setting. The biphasic dose-response (neuroprotective at low doses, antidepressant at high doses) creates dosing complexity that community users cannot safely manage with research chemical preparations.

PE-22-28 is the kind of compound that pharmaceutical development pipelines were designed for—a clear target, a potent and selective compound, a novel mechanism, and consistent preclinical efficacy. What it needs is human clinical trials. What it has is peptide vendor marketing. The gap between those two things is the distance between interesting science and evidence-based medicine.

Verdict Recapitulation

Clear pharmacology. Consistent preclinical effects. Genuine mechanistic novelty. But zero human data, single-lab evidence, and a biphasic dose-response that complicates community use. Eyes open—the compound deserves clinical investigation, not premature adoption.

For readers considering PE-22-28, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source PE-22-28

Further Reading and Resources

If you want to go deeper on PE-22-28, the evidence landscape for cognitive & neuroprotective peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Cognitive & Neuroprotective Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: PE-22-28 — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Djillani A, Mazella J, Heurteaux C, Borsotto M. "Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activity." Frontiers in Pharmacology, 8, 643 (2017). PMID 28955242
2. Djillani A, Pietri M, Mazella J, Heurteaux C, Bhatt DK. "First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides." Neuropharmacology, 158, 107715 (2019). PMID 31325429
3. Mazella J, Pétrault O, Lucas G, et al. "Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design." PLoS Biology, 8(4), e1000355 (2010). PMID 20405001
4. Bhatt DK, Gupta S, Jansen-Olesen I, et al. "Sortilin deficiency alters TREK-1 function and decreases depressive-like behavior in mice." Molecular Psychiatry, 23(8), 1813–1821 (2018). PMID 30127743
5. Heurteaux C, Guy N, Laigle C, et al. "TREK-1, a K+ channel involved in neuroprotection and general anesthesia." EMBO Journal, 23(13), 2684–2695 (2004)

---